|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||0.4500 - 0.4900|
|52 Week Range||0.1426 - 2.1700|
|Beta (3Y Monthly)||5.08|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The Company will issue US$300.0 million aggregate principal amount of notes, or US$345.0 million aggregate principal amount if the initial purchasers' over-allotment option is exercised in full. Aurora expects to use the net proceeds from the offering of the notes to support its Canadian and international expansion initiatives, for future acquisitions and for general corporate purposes, including working capital requirements to continue the Company's accelerated growth.
Aurora also intends to grant to the initial purchasers of the notes an option to purchase up to an additional US$37.5 million aggregate principal amount of notes. Aurora expects to use the net proceeds from the offering of the notes to support its Canadian and international expansion initiatives, for future acquisitions and for general corporate purposes, including working capital requirements to continue the Company's accelerated growth. The final terms of the notes will be determined by Aurora and the initial purchasers.
CTT Pharmaceutical Holdings, Inc., (“CTT”) (CTTH), an innovative life sciences company with a portfolio of IP in novel drug delivery systems, is pleased to announce that it has filed national patent applications that encompass over 50 countries for its titled “Orally Administrable Composition” technology. This patent application broadly covers products such as Oral Thin Films, Wafers, Strips, Tablets, Gums etc. that deliver active nanonized pharmaceuticals including cannabinoids, opioids and most other large therapeutic molecules. “The initial patentability opinion received from the PCT office was positive, underscoring the novel nature of our technology and affirming our outlook to obtain patent acceptance in other countries in due course,” said Cam Birge, CEO of CTT Pharmaceutical.
WKN: A1C4WM) today provided an expected revenue range for the second quarter of the Company's Fiscal 2019 ("Q2 2019"), the period ended December 31, 2018 . Based on preliminary (unaudited) results, the Company anticipates revenues for Q2 2019 of between $50 million and $55 million (net of excise taxes), compared to $11.7 million for the same quarter in the prior year, and compared to $29.7 million for the previous quarter ended September 30, 2018 ("Q1 2019"). The results reflect an anticipated revenue growth rate in excess of 327% compared to Q2 2018 and in excess of 68% compared to Q1 2019.
/THE SECURITIES HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS AND MAY NOT BE OFFERED OR SOLD WITHIN THE UNITED STATES ABSENT SUCH REGISTRATION OR AN APPLICABLE EXEMPTION FROM SUCH REGISTRATION REQUIREMENTS. WKN: A1C4WM) ("Aurora") as well as 1,330 Debentures to other Offering participants for gross proceeds to date of $11,330,000 .
WKN: A1C4WM) announced today that, further to the Company's press release dated December 7, 2018 , the Company has entered into a Letter of Intent to acquire all of the issued and outstanding shares of Farmacias Magistrales S.A. ("Farmacias"), subject to customary due diligence provisions, the completion of definitive agreements, and regulatory and government approval. As previously announced, Farmacias recently became Mexico's first and only federally licensed importer to date of raw materials containing THC, gaining the necessary licenses, facilities, and permissions to import raw THC material, and manufacture, store, and distribute medical cannabis products containing over 1% THC.
Aurora Cannabis to Enter Mexico Market via Exclusive Supply Arrangement with Farmacias Magistrales
WKN: A1C4WM) announced today that the company, through a selling broker, has completed the sale in the open market of the Australis Capital Inc. ("Australis") units on behalf of non-resident shareholders. Payment of the net cash proceeds from the sales of Australis units to the non-resident shareholders of record as of August 24, 2018 was completed by the custodian on November 27, 2018 . In total, 11,222,349 units of Australis were sold in the public markets.
WKN: A1C4WM) announced today that the company has received an export request, has secured the required export permit and has now completed its first shipment of medical cannabis products to the Czech Republic , making this the 21st country in which the company operates. The initial purchase order was placed by, and products will be shipped to Czech Medical Herbs s.r.o. Czech Medical Herbs is a distributor of medicinal products with a specialization in Cannabis for medical use and medicinal products based on cannabinoids.
WKN: A1C4WM) and ICC Labs Inc. (ICC.V) ("ICC") are pleased to announce today the completion of the previously announced plan of arrangement (the "Arrangement") pursuant to which Aurora has acquired all of the issued and outstanding common shares of ICC for $1.95 per share (payable in common shares of Aurora (the "Aurora Shares")), reflecting an aggregate purchase price of approximately $290 million . ICC is now a wholly-owned subsidiary of Aurora.
This Order from Aurora is for a customized line of smoking accessories across multiple categories including bubblers, grinders, hand pipes, hemp wicks, sherlocks, vaporizers and water pipes. High Tide has commenced the process of converting its proprietary designs into manufactured products for its new client.
At 48,000 square feet, with 11 purpose-built grow rooms, Aurora Eau will produce up to 4,500 kg of high quality cannabis per year, all in a facility with some of the lowest electricity costs in North America . It is designed to grow niche varieties of cannabis for the premium medical and adult consumer use markets in Quebec, Canada and around the world.
OTCQB: CHOOF) ( "Choom") an emerging adult use cannabis company that has secured one of the largest retail networks in Canada , are pleased to announce that the companies have completed a non-brokered private placement of a debenture (the "Offering") in the principal amount of $20,000,000 in Choom by Aurora, convertible into common shares of Choom ("Common Shares") at a conversion price of $1.25 per Common Share, with a four year maturity date.
WKN: A1C4WM) and ICC Labs Inc. ( ICC ) (ICC.V) are pleased to announce that Aurora has received, from its consortium of lenders led by Bank of Montreal (collectively, the Lenders), consent and approval as required under its credit agreement with the Lenders to the previously announced plan of arrangement (the Arrangement) between ICC and Aurora. Subject to the terms and conditions of the arrangement agreement dated September 8, 2018 (the Arrangement Agreement), Aurora will acquire all of the issued and outstanding common shares (ICC Shares) of ICC.
WKN: A1C4WM) announced today that Polish Ministry of Health granted the Company approval for its first shipment of medical cannabis to Poland . In the coming days, Aurora Deutschland GmbH will ship the products to a pain treatment center and a hospital in Warsaw . This is an important milestone for medical patients in Poland , as it is believed to be the first time a non-government run business has been granted approval to supply medical cannabis products in the country.